Showing results (321-330 of 369) with videos related to
Sort By:
Pageof 37
Oncoimmunology|December 14, 2020
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1Neeta Somaiah, Sant P Chawla, Matthew S Block, et al.Journal for Immunotherapy of Cancer|September 1, 2021
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomesBrett A Schroeder, Natalie A LaFranzo, Bonnie J LaFleur, et al.Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.JAMA|April 8, 2020
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical TrialWilliam D Tap, Andrew J Wagner, Patrick Schöffski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUEMichael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 TrialPatrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.Journal for Immunotherapy of Cancer|May 8, 2021
IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapyKaran Kohli, Lu Yao, Theodore Scott Nowicki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue SarcomaChristopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2024
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 SuppressionSilvia Stacchiotti, Silvia Martini, Sandro Pasquali, et al.European Journal of Cancer (Oxford, England : 1990)|January 4, 2023
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022Christian Rothermundt, Dimosthenis Andreou, Jean-Yves Blay, et al.Pageof 37